Last reviewed · How we verify
Placebo (Saxagliptin)
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones to stimulate the release of insulin and decrease the release of glucagon.
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones to stimulate the release of insulin and decrease the release of glucagon. Used for Type 2 diabetes.
At a glance
| Generic name | Placebo (Saxagliptin) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This action results in a decrease in blood glucose levels. Saxagliptin is used in combination with other medications to improve glycemic control in patients with type 2 diabetes. It is also used as a placebo in clinical trials to compare its efficacy with active treatments.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Headache
- Muscle pain
- Fatigue
Key clinical trials
- Effects of Saxagliptin on Adipose Tissue Inflammation in Humans (PHASE4)
- Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old (PHASE3)
- Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Effects of DPP-4 Inhibition on Triglycerides (PHASE4)
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin (PHASE3)
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (PHASE4)
- Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes (PHASE2)
- DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (Saxagliptin) CI brief — competitive landscape report
- Placebo (Saxagliptin) updates RSS · CI watch RSS
- AstraZeneca portfolio CI